Core Viewpoint - The company is experiencing short-term performance pressure due to internal adjustments, with a significant decline in 2024 revenue and net profit, but a narrowing of the decline in Q1 2025 [1] Financial Performance - In 2024, the company achieved revenue of 5.679 billion, down 13.93% year-on-year; net profit attributable to shareholders was -0.833 billion, down 266.60% year-on-year; and non-recurring net profit was -0.838 billion, down 366.41% year-on-year [1] - In Q1 2025, the company reported revenue of 1.704 billion, down 10.59% year-on-year; net profit attributable to shareholders was 0.217 billion, down 15.25% year-on-year; and non-recurring net profit was 0.192 billion, down 34.49% year-on-year [1] Segment Performance - In Q1 2025, the beauty segment generated revenue of 0.329 billion, up 10.7% year-on-year, accounting for 19.3% of total revenue, despite a 65.4% decline in average price due to inventory clearance [2] - The personal care segment achieved revenue of 0.791 billion, with an average price decline of 13.4% [2] - The innovation/overseas segments generated revenues of 0.233 billion and 0.347 billion, respectively [2] Channel Performance - In Q1 2025, online channels saw a revenue growth of 10.4%, with a revenue share of 29%, up 5.5 percentage points year-on-year; brands like Yuzai, Liushen, and Baicaojie experienced triple-digit growth in GMV on Douyin [2] - The company expanded its emerging channels by opening 38,000 new stores in Q1, with sales in these channels growing by double digits year-on-year, aiming to complete a target of 10,000 stores in the first half of the year [2] Profitability and Cost Structure - In 2024, the company's gross margin and net margin decreased by 1.37 and 22.25 percentage points year-on-year, respectively; in Q1 2025, gross margin increased by 0.14 percentage points, while net margin slightly declined by 0.70 percentage points due to inventory adjustments and increased marketing expenses [2] - The expense ratios for sales, management, and R&D increased year-on-year in both 2024 and Q1 2025, primarily due to revenue pressure [2] Employee Stock Ownership Plan - The company has introduced an employee stock ownership plan for up to 45 core management members, with a buyback price of 16.03 yuan per share; the CEO and CFO plan to subscribe for a maximum of 1.008 million shares, accounting for 20.85% of the total [3] - The plan will unlock in three phases, with performance targets tied to achieving positive net profit in 2025 and a year-on-year growth of no less than 10% in 2026-2027 [3]

Core Viewpoint - The company reported a significant decline in revenue and a net loss for 2024, with expectations for gradual improvement in 2025 as it undergoes strategic organizational transformation [1][2]. Financial Performance - In 2024, the company achieved revenue of 5.679 billion yuan, a year-on-year decrease of 13.9%, and a net loss of 0.833 billion yuan, marking a shift from profit to loss [1]. - For Q1 2025, revenue was 1.704 billion yuan, down 10.6% year-on-year, while net profit was 0.217 billion yuan, a decrease of 15.3% year-on-year [1]. Strategic Initiatives - The company faced challenges in 2024 due to goodwill impairment from overseas operations, strategic adjustments in domestic business, and a decline in uncontrollable investment income, leading to a net loss [2]. - The profit fluctuations in Q1 2025 were primarily due to adjustments in pricing strategies and delays in inventory replenishment by offline distributors, although overall demand remained unaffected [2]. - The company is actively responding to industry changes by promoting online transformation and implementing strategic adjustments in offline channels, with expectations for transformation results to gradually materialize in 2025 [2]. Employee Engagement - The company announced an employee stock ownership plan, allowing for a maximum of 4.8351 million shares (0.72% of total shares) to be allocated to up to 45 employees, sourced from repurchased shares at an average price of 16.03 yuan per share [3]. - The performance targets associated with the stock ownership plan include achieving profitability in 2025 and maintaining a net profit growth rate of no less than 10% for 2026-2027 [3]. - This plan aims to enhance employee cohesion and company competitiveness, motivating employees and fostering long-term sustainable development [3]. Profit Forecast and Investment Outlook - The company forecasts revenues of 6.422 billion yuan, 7.399 billion yuan, and 8.294 billion yuan for 2025, 2026, and 2027, respectively, with growth rates of 13.1%, 15.2%, and 12.1% [4]. - Expected net profits for the same years are projected at 0.366 billion yuan, 0.484 billion yuan, and 0.642 billion yuan, indicating a return to profitability in 2025 and growth rates of 32.3% and 32.5% for 2026 and 2027 [4]. - Earnings per share (EPS) are anticipated to be 0.54 yuan, 0.72 yuan, and 0.95 yuan for 2025, 2026, and 2027, respectively, as the company undergoes adjustments across various dimensions [4].

Group 1 - Shanghai Jahwa expresses confidence in achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover rates, and foster a sense of ownership among employees [1] - Strategic adjustments over the past six months include clear strategy formulation, organizational design alignment, talent development, and cultural building [1] Group 2 - E-commerce initiatives involve inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The Yuze B5 series is planned to be a key product line on JD.com [1] - Efficiency improvements have been noted in terms of product effectiveness, personnel effectiveness, e-commerce services, and operational quality [1] Group 3 - The company aims for double-digit revenue growth this year and to turn profits from losses [1] - The mosquito repellent product line will increase its online presence and expand offline distribution [1] - Long-term profit recovery is projected to follow a timeline of 1-2 years for revenue growth, 2-3 years for profit improvement, and 3-5 years to meet profit margin targets [1] Group 4 - The main brand Yuze is positioned as an expert in skin barrier repair, while Liushen is expanding its usage scenarios and target demographics [1]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover rates, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies have been refined, including inventory management, pricing adjustments, organizational restructuring, and product iterations [1] - The Yuze B5 series is planned to be a key product line on JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a timeline of 1-2 years for revenue growth, 2-3 years for profit improvement, and 3-5 years to meet profit margin targets [1] - The main brand Yuze is positioned as a skin barrier repair expert, while Liushen is expanding its usage scenarios and target demographics [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest developments and future plans for the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approvals from NMPA and FDA, showing promising early efficacy [2] - ZG005 is one of the first drugs in clinical research targeting the same pathway, with multiple clinical studies underway [2] - ZGGS18 has completed the dose escalation in Phase I trials in China and is currently in Phase I/II clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] - Zai Lab also discussed the sales progress and future expectations for recombinant human thrombin and the approval status of recombinant human thyroid-stimulating hormone [2] Group 3: Company Overview - Shenzhen Zhongou Ruibo Investment Management Co., Ltd. was established in 2007 and is one of the earliest private equity fund management companies in China [3] - The company focuses on secondary market securities investment and has launched over 50 private equity products in collaboration with top domestic financial institutions [3] - It obtained private fund manager qualifications in 2014 and launched its first overseas fund in 2016 [3] - The name "Rabbit Fund" reflects the company's investment culture of risk management, emphasizing the importance of risk prevention and management [3] - The investment philosophy is centered on growing alongside great companies and adapting strategies to respect market trends [3] - The company has received numerous accolades for its performance, including the "Morningstar Award" and "Golden Bull Award" [3]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The company has implemented strategic adjustments over the past six months, including organizational design, talent development, and cultural construction [1] - The employee stock ownership plan aims to enhance competitiveness and reduce turnover [1] - E-commerce strategies include inventory optimization, price adjustments, and product iterations, with the Yuze B5 series positioned as a key product line on JD.com [1] - The company targets double-digit revenue growth this year and aims to turn profits around [1] - Long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Yingjie Electric - Yingjie Electric expects revenue of 1.78 billion yuan in 2024, a year-on-year increase of 0.59%, but a 25.19% decline in net profit attributable to shareholders [2] - Delays in revenue recognition in the photovoltaic industry and increased costs have impacted performance [2] - The company reported a net cash flow from operating activities of 601.77 million yuan, an increase of 462.05 million yuan year-on-year [2] - Inventory has decreased to 1.556 billion yuan, with contract liabilities maintained around 1.1 billion yuan [2] - New orders have decreased by approximately 40%, but the company has over 2.7 billion yuan in hand orders [2] - The company aims to confirm overseas photovoltaic orders by 2025, with expected revenue pressure but not a significant decline [2] - The semiconductor advanced process power products have begun mass production, with projected revenue of 350 million yuan in 2024 [2] - R&D investment is high, focusing on semiconductor development, with new hires primarily in this area [2] - Financial risks are manageable, with most photovoltaic payments received [2] - The company targets 5 billion yuan in revenue within the next 3-4 years and aims to enter the top 100 private enterprises in Sichuan [2]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - Recent strategic adjustments include clarifying strategy, aligning organizational design, building talent teams, and cultural development [1] - E-commerce initiatives involve inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The Yuze B5 series is planned as a key product line for JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest progress and future plans for R&D, commercialization, and internationalization over the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approval from NMPA and FDA, showing promising early efficacy [2] - ZG005 is among the first drugs in clinical research targeting the same pathway, with multiple clinical studies ongoing [2] - ZGGS18 has completed the I phase dose escalation in China and is currently in I/II phase clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] Group 3: Aladdin - Aladdin has achieved several domestic product replacements through independent R&D and innovation, enhancing its competitive edge [3] - The company collaborates with Yuan Ye and Fei Peng to share resources, expand business scale, and improve overall competitiveness [3] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, and expanding overseas markets and biological reagent business [3] - Revenue growth in the life sciences sector is primarily driven by the merger with Yuan Ye Bio, increasing sales of major life science products [3] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [3] Group 4: Company Overview - Shanghai Licheng Asset is one of the earliest established private equity management companies in China, focusing on growth stock investment with a safety margin approach [4] - The company has a complete and unique investment management knowledge system, with a team of 50 employees, nearly 30 of whom are professional research analysts [4] - The management scale has exceeded 10 billion yuan, specializing in secondary stock long strategies and PIPE strategies in the pharmaceutical, advanced manufacturing, and consumer sectors [4] - Licheng has consistently ranked high in long-term performance and has received multiple private equity awards [4]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies include inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The company targets double-digit revenue growth this year and aims to turn profits around [1] - Long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zhuoyi Information - Zhuoyi Information has approximately 7,000 active users for its SnapDevelop platform and plans to release a paid commercial version [2] - EazyDevelop, which focuses on rapid development using AI technology, will have a free trial version available after development [2] - The company has made breakthroughs in RISC-V firmware and is collaborating with major firms like Huawei and Lenovo [2] Group 3: Chipbond Technology - Chipbond Technology has made progress in advanced packaging, with its WLP2000 equipment entering mass production preparation after client validation [3] - The company benefits from advantageous direct-write lithography technology and has seen a 22.31% year-on-year increase in revenue and a 30.45% increase in net profit in Q1 [3] - The company expects overseas orders to account for nearly 20% by 2024, indicating strong international market competitiveness [3] Group 4: Kanghong Pharmaceutical - Kanghong Pharmaceutical's KPB-101 has established a leading position in China's ophthalmic anti-VEGF market and aims for further achievements [4] - The company focuses on diverse research and development in ophthalmology, neurology, and oncology, with a strong emphasis on innovative drug sales [4] - The company anticipates a revenue and net profit growth of 5%-15% year-on-year by 2025, with specific products expected to see significant sales growth [4]

Core Viewpoint - Domestic beauty brands are gaining competitive advantages in the market through high cost-performance ratios and refined operations [1][7]. Group 1: Market Performance - In early 2024, the retail sales of cosmetics in China are projected to be 435.7 billion yuan, a year-on-year decline of 1.1% [2]. - Despite the overall market stagnation, several domestic beauty companies have reported impressive performance, with Proya (603605.SH) achieving a revenue of 10.778 billion yuan, a year-on-year increase of 21.04% [2][3]. - Other established beauty companies such as Shiseido (02145.HK), Maogeping (01318.HK), and Marubi (603983.SH) also reported revenue growth exceeding 20% [2]. Group 2: Online Sales Strategy - Leading beauty companies are increasingly focusing on online sales, with Proya's online sales ratio exceeding 95% and sales surpassing 10 billion yuan [4]. - Shiseido's online sales ratio is over 90%, with sales exceeding 6 billion yuan, while Marubi's online sales ratio is above 85% [4]. - In the e-commerce landscape, Douyin has emerged as a significant player, with total beauty sales reaching between 2.5 billion to 5 billion units and total sales exceeding 100 billion yuan [4]. Group 3: Quarterly Performance - In Q1 2025, the retail sales of cosmetics reached 114.9 billion yuan, a year-on-year increase of 3.2% [6]. - Proya reported a Q1 2025 revenue of 2.359 billion yuan, up 8.13% year-on-year, and a net profit of 390 million yuan, up 28.87% [6]. - Marubi achieved a Q1 2025 revenue of 847 million yuan, a year-on-year increase of 28.01%, with a net profit of 135 million yuan, up 22.07% [6]. Group 4: Future Outlook - The management of Juzhi Biological aims for a revenue growth of 25% to 28% and a net profit growth of 21% to 24% for the 2025 fiscal year [7]. - The cosmetics and medical beauty industry is expected to show stable growth driven by policy support and consumer recovery [7]. - Domestic beauty brands are focusing on reducing traffic costs and enhancing digital marketing strategies to ensure measurable business growth [7].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][21]. Core Views - The company's performance in Q1 2025 shows a narrowing decline, with revenue of 1.704 billion and a year-on-year decrease of 10.59%. The net profit attributable to the parent company is 217 million, down 15.25% year-on-year [6][7]. - The company is undergoing internal adjustments, which have led to short-term performance pressure. The significant decline in 2024 is primarily due to goodwill impairment of 610 million related to previous acquisitions and strategic adjustments in domestic operations [6][20]. - The company has implemented an employee stock ownership plan to bind core management, with a total of 45 participants and a repurchase price of 16.03 yuan per share [3][9]. Summary by Sections Financial Performance - In 2024, the company achieved revenue of 5.679 billion, a year-on-year decrease of 13.93%, and a net profit of -833 million, down 266.60% year-on-year. The Q4 performance showed revenue of 1.202 billion, down 20.20% year-on-year [6][7]. - For Q1 2025, the beauty segment generated revenue of 329 million, up 10.7% year-on-year, while the personal care segment generated 791 million, with an average price decline of 13.4% [2][8]. - The company’s gross margin for 2024 was 57.60%, down 1.37 percentage points year-on-year, while Q1 2025 saw a slight increase in gross margin to 63.40% [11][13]. Strategic Adjustments - The company is actively adjusting its pricing strategy and optimizing channel inventory, which has led to a delay in the purchasing rhythm of distributors [7][20]. - The company plans to expand its emerging channels, having opened 38,000 new stores in Q1 2025, with sales in these channels growing by double digits year-on-year [2][8]. Profitability and Valuation - The company has revised its net profit forecasts for 2025, 2026, and 2027 to 433 million, 504 million, and 581 million respectively, with corresponding P/E ratios of 35, 30, and 26 times [21][23]. - The company’s total market capitalization is 15.327 billion, with a closing price of 22.80 yuan [5][22].

Core Viewpoint - Shanghai Jahwa has undergone significant transformation under the leadership of new Chairman and CEO Lin Xiaohai, focusing on strategic adjustments and operational efficiency to enhance long-term growth potential despite short-term financial pressures [1][2][5]. Financial Performance - In 2024, Shanghai Jahwa reported revenue of 5.679 billion yuan and a net profit attributable to shareholders of -833 million yuan, with Q1 2025 revenue at 1.704 billion yuan and a net profit of 217 million yuan [1][4]. - The decline in profit was primarily due to a goodwill impairment of 613 million yuan related to the overseas baby care brand, Tommee Tippee, and proactive adjustments in domestic channel structures [4]. Strategic Focus - The company has implemented a "Four Focus" strategy, emphasizing core brand development, brand building, online growth, and operational efficiency to regain growth momentum [2][5]. - A significant shift towards online channels has been noted, with online revenue reaching 2.539 billion yuan in 2024, accounting for 44.7% of total revenue, an increase of 2 percentage points year-on-year [6]. Brand Development - Core brands such as Yuze and Liushen have shown strong performance, driving the company's revenue rebound [7][10]. - Yuze has undergone a comprehensive upgrade in brand image and product formulation, resulting in significant sales growth shortly after the launch of new products [8][9]. Research and Development - In 2024, Shanghai Jahwa invested 179 million yuan in R&D, representing 3.16% of revenue, and secured 73 new patents, marking a 55% increase from the previous year [11]. - The company is focusing on innovative research methods and collaborations with academic institutions to enhance product development and safety [12][13].